These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28485202)

  • 1. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
    J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28485202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
    J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
    G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
    Kanda E; Rastogi A; Murohara T; Lesén E; Agiro A; Arnold M; Chen G; Yajima T; Järbrink K; Pollack CV
    BMC Nephrol; 2023 Jan; 24(1):18. PubMed ID: 36658531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
    Wang AY
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study.
    Stawowczyk E; Ward T; Paoletti E; Senni M; de Arellano AR
    Cost Eff Resour Alloc; 2024 May; 22(1):42. PubMed ID: 38769560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A; An A; Cook EE; Mu F; Chen J; Desai P; Oluwatosin Y; Pollack CV
    Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Model to Predict Risk of Hyperkalemia in Patients with Chronic Kidney Disease Using a Large Administrative Claims Database.
    Sharma A; Alvarez PJ; Woods SD; Dai D
    Clinicoecon Outcomes Res; 2020; 12():657-667. PubMed ID: 33204127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study.
    Volterrani M; Perrone V; Sangiorgi D; Giacomini E; Iellamo F; Degli Esposti L;
    Eur J Heart Fail; 2020 Nov; 22(11):2049-2055. PubMed ID: 33459467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain.
    González-Juanatey JR; González-Franco Á; de Sequera P; Valls M; Ramirez de Arellano A; Pomares E; Nieves D
    J Med Econ; 2022; 25(1):640-649. PubMed ID: 35510569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
    Dwyer JP; Agiro A; Desai P; Oluwatosin Y
    Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.
    de Sequera P; Bover R; Ivanova-Markova Y; Ivanova A; González-Domínguez A; Valls M; Campos V
    Nefrologia (Engl Ed); 2023; 43(6):721-730. PubMed ID: 38228463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and clinical impact of hyperkalaemia within a large, modern, real-world heart failure population.
    Muhlestein JB; Kammerer J; Bair TL; Knowlton KU; Le VT; Anderson JL; Lappé DL; May HT
    ESC Heart Fail; 2021 Feb; 8(1):691-696. PubMed ID: 33331114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
    PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world management of hyperkalemia with patiromer among United States Veterans.
    Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
    Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
    Desai NR; Rowan CG; Alvarez PJ; Fogli J; Toto RD
    PLoS One; 2020; 15(1):e0226844. PubMed ID: 31910208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.